New directions in natural killer cell-based immunotherapy of human cancer

Sherif Farag, Todd A. Fehniger, Brian Becknell, Bradley W. Blaser, Michael A. Caligiuri

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Efforts at harnessing the antitumour activity of natural killer (NK) cells have been investigated for the immunotherapy of human cancer for over two decades. Initial trials, focusing on the use of ex vivo-generated lymphokine activated killer (LAK) cells or activated NK cells, or in vivo cytokine therapy to expand and activate NK cells against autologous tumours, have yielded only modest success. Recent understanding of the means by which NK cells kill target cells through a complex set of activating and inhibitory receptors recognising corresponding ligands on tumour cells has paved the way for the design of improved strategies for NK cell-based immunotherapy. The net balance of activating and inhibitory signals through NK cell receptors determines whether an NK cell becomes activated or not. Successful therapeutic strategies should now focus on manipulating the balance in favour of activating receptor signalling. In the case of autologous cancers, such strategies may include the use of monoclonal antibodies with cytokines to better direct NK cells to their tumour targets through the process of antibody-dependent cellular cytotoxicity (ADCC) or the in vivo blocking of inhibitory interactions between NK receptors (NKRs) and ligands on tumour cells. Alternatively, allogeneic NK cells can be used whenever there is mismatching of inhibitory NK cell receptors and ligands. Finally, methods to modulate expression of NK cell receptors and their ligands on tumour cells by cytokines and other agents should be explored. In this review, the impact of NKR biology on the development of novel strategies for the use of NK cells in the treatment of human cancer is discussed.

Original languageEnglish (US)
Pages (from-to)237-250
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume3
Issue number2
DOIs
StatePublished - Apr 2003
Externally publishedYes

Fingerprint

Natural Killer Cells
Immunotherapy
Tumors
Natural Killer Cell Receptors
Ligands
Cells
Neoplasms
Cytokines
Lymphokines
Cytotoxicity
Monoclonal Antibodies
Direction compound
Lymphokine-Activated Killer Cells
Antibodies
Therapeutics

Keywords

  • Cancer
  • Immumotherapy
  • Interleukin-2
  • NK cells
  • Transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

New directions in natural killer cell-based immunotherapy of human cancer. / Farag, Sherif; Fehniger, Todd A.; Becknell, Brian; Blaser, Bradley W.; Caligiuri, Michael A.

In: Expert Opinion on Biological Therapy, Vol. 3, No. 2, 04.2003, p. 237-250.

Research output: Contribution to journalArticle

Farag, Sherif ; Fehniger, Todd A. ; Becknell, Brian ; Blaser, Bradley W. ; Caligiuri, Michael A. / New directions in natural killer cell-based immunotherapy of human cancer. In: Expert Opinion on Biological Therapy. 2003 ; Vol. 3, No. 2. pp. 237-250.
@article{b0420f72b2cb4e0bbceb81c3268a5289,
title = "New directions in natural killer cell-based immunotherapy of human cancer",
abstract = "Efforts at harnessing the antitumour activity of natural killer (NK) cells have been investigated for the immunotherapy of human cancer for over two decades. Initial trials, focusing on the use of ex vivo-generated lymphokine activated killer (LAK) cells or activated NK cells, or in vivo cytokine therapy to expand and activate NK cells against autologous tumours, have yielded only modest success. Recent understanding of the means by which NK cells kill target cells through a complex set of activating and inhibitory receptors recognising corresponding ligands on tumour cells has paved the way for the design of improved strategies for NK cell-based immunotherapy. The net balance of activating and inhibitory signals through NK cell receptors determines whether an NK cell becomes activated or not. Successful therapeutic strategies should now focus on manipulating the balance in favour of activating receptor signalling. In the case of autologous cancers, such strategies may include the use of monoclonal antibodies with cytokines to better direct NK cells to their tumour targets through the process of antibody-dependent cellular cytotoxicity (ADCC) or the in vivo blocking of inhibitory interactions between NK receptors (NKRs) and ligands on tumour cells. Alternatively, allogeneic NK cells can be used whenever there is mismatching of inhibitory NK cell receptors and ligands. Finally, methods to modulate expression of NK cell receptors and their ligands on tumour cells by cytokines and other agents should be explored. In this review, the impact of NKR biology on the development of novel strategies for the use of NK cells in the treatment of human cancer is discussed.",
keywords = "Cancer, Immumotherapy, Interleukin-2, NK cells, Transplantation",
author = "Sherif Farag and Fehniger, {Todd A.} and Brian Becknell and Blaser, {Bradley W.} and Caligiuri, {Michael A.}",
year = "2003",
month = "4",
doi = "10.1517/14712598.3.2.237",
language = "English (US)",
volume = "3",
pages = "237--250",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - New directions in natural killer cell-based immunotherapy of human cancer

AU - Farag, Sherif

AU - Fehniger, Todd A.

AU - Becknell, Brian

AU - Blaser, Bradley W.

AU - Caligiuri, Michael A.

PY - 2003/4

Y1 - 2003/4

N2 - Efforts at harnessing the antitumour activity of natural killer (NK) cells have been investigated for the immunotherapy of human cancer for over two decades. Initial trials, focusing on the use of ex vivo-generated lymphokine activated killer (LAK) cells or activated NK cells, or in vivo cytokine therapy to expand and activate NK cells against autologous tumours, have yielded only modest success. Recent understanding of the means by which NK cells kill target cells through a complex set of activating and inhibitory receptors recognising corresponding ligands on tumour cells has paved the way for the design of improved strategies for NK cell-based immunotherapy. The net balance of activating and inhibitory signals through NK cell receptors determines whether an NK cell becomes activated or not. Successful therapeutic strategies should now focus on manipulating the balance in favour of activating receptor signalling. In the case of autologous cancers, such strategies may include the use of monoclonal antibodies with cytokines to better direct NK cells to their tumour targets through the process of antibody-dependent cellular cytotoxicity (ADCC) or the in vivo blocking of inhibitory interactions between NK receptors (NKRs) and ligands on tumour cells. Alternatively, allogeneic NK cells can be used whenever there is mismatching of inhibitory NK cell receptors and ligands. Finally, methods to modulate expression of NK cell receptors and their ligands on tumour cells by cytokines and other agents should be explored. In this review, the impact of NKR biology on the development of novel strategies for the use of NK cells in the treatment of human cancer is discussed.

AB - Efforts at harnessing the antitumour activity of natural killer (NK) cells have been investigated for the immunotherapy of human cancer for over two decades. Initial trials, focusing on the use of ex vivo-generated lymphokine activated killer (LAK) cells or activated NK cells, or in vivo cytokine therapy to expand and activate NK cells against autologous tumours, have yielded only modest success. Recent understanding of the means by which NK cells kill target cells through a complex set of activating and inhibitory receptors recognising corresponding ligands on tumour cells has paved the way for the design of improved strategies for NK cell-based immunotherapy. The net balance of activating and inhibitory signals through NK cell receptors determines whether an NK cell becomes activated or not. Successful therapeutic strategies should now focus on manipulating the balance in favour of activating receptor signalling. In the case of autologous cancers, such strategies may include the use of monoclonal antibodies with cytokines to better direct NK cells to their tumour targets through the process of antibody-dependent cellular cytotoxicity (ADCC) or the in vivo blocking of inhibitory interactions between NK receptors (NKRs) and ligands on tumour cells. Alternatively, allogeneic NK cells can be used whenever there is mismatching of inhibitory NK cell receptors and ligands. Finally, methods to modulate expression of NK cell receptors and their ligands on tumour cells by cytokines and other agents should be explored. In this review, the impact of NKR biology on the development of novel strategies for the use of NK cells in the treatment of human cancer is discussed.

KW - Cancer

KW - Immumotherapy

KW - Interleukin-2

KW - NK cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0037391786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037391786&partnerID=8YFLogxK

U2 - 10.1517/14712598.3.2.237

DO - 10.1517/14712598.3.2.237

M3 - Article

C2 - 12662139

AN - SCOPUS:0037391786

VL - 3

SP - 237

EP - 250

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 2

ER -